Lipid changes on hormone therapy and coronary heart disease events in the Heart and Estrogen/progestin Replacement Study (HERS) - 28/08/11
, Lily A Chaput, MD, MPH c, Eric Vittinghoff, PhD c, Feng Lin, MS c, Vera Bittner, MD d, Robert H Knopp, MD e, Stephen B Hulley, MD, MPH cHeart and Estrogen/progestin Replacement Study (HERS) Investigators
Abstract |
Background |
Despite the effect of lowering low-density lipoprotein cholesterol (LDL-C) levels and raising high-density lipoprotein cholesterol (HDL-C) levels, combination hormone therapy did not reduce the incidence of coronary heart disease (CHD) events in the Heart and Estrogen/progestin Replacement Study (HERS). To explore possible mechanisms, we examined the association between lipid changes and CHD outcomes among women assigned to hormone therapy.
Methods |
HERS participants were postmenopausal women with previously diagnosed CHD who were randomly assigned to receive conjugated estrogens and medroxyprogesterone or identical placebo and then followed-up for an average of 4.1 years. Among women assigned to hormone therapy, associations between baseline-to-year-1 lipid level changes and CHD events were compared with the associations observed for baseline lipids using multivariate proportional hazards models.
Results |
Among women assigned to hormone therapy, CHD events were independently predicted by baseline LDL-C levels (relative hazard [RH] 0.94 per 15.6 mg/dL decrease, 95% CI 0.88–1.01) and HDL-C levels (RH 0.89 per 5.4 mg/dL increase, 95% CI 0.81–0.99), but not by triglyceride levels (RH 1.01 per 13.2mg/dL increase, 95% CI 0.97–1.06). CHD events were marginally associated with first-year reductions in LDL-C levels (RH 0.95 per 15.6mg/dL decrease, 95% CI 0.86–1.04), and were not associated with increases in HDL-C levels ( RH 1.03 per 5.4 mg/dL increase, 95% CI 0.91–1.16) or triglyceride levels (RH 1.01 per 13.2 mg/dL increase, 95% CI 0.98–1.05).
Conclusion |
Changes in lipid levels with hormone therapy are not predictive of CHD outcomes in women with heart disease in the HERS trial.
Le texte complet de cet article est disponible en PDF.Plan
 | HERS was supported by a contract with Wyeth-Ayerst Research (Radnor, Pa). Dr. Shlipak is a recipient of a Research Career Development Award from the Veterans Administration division of Health Services Research and Development. |
Vol 146 - N° 5
P. 870-875 - novembre 2003 Retour au numéro
Article précédent
- Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: Results of the Comparative HDL Efficacy and Safety Study (CHESS)
- Christie M Ballantyne, Michael A Blazing, Donald B Hunninghake, Michael H Davidson, Zhong Yuan, Paul DeLucca, Karen E Ramsey, Carolyn M Hustad, Joanne Palmisano
- Statin use is associated with enhanced collateralization of severely diseased coronary arteries
- Isaac Pourati, Carey Kimmelstiel, William Rand, Richard H Karas
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?